Status:
UNKNOWN
Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Conditions:
EGFR Mutation Positive Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The investigators wish to document the distribution of EGFR somatic mutations, and assess the relationship between specific genotype, clinical demographic, therapy, and survival, in a large cohort of ...
Detailed Description
Objective 1: To identify germline allelic DNA variation associated with somatic EGFR mutation in NSCLC, Objective 2: Correlation between germline allelic variants and survival in EGFR somatic mutant N...
Eligibility Criteria
Inclusion
- Histologically or cytologically diagnosed NSCLC, all histologies are acceptable.
- Patients can be included in the study with any disease stage and at any time during the disease course.
- Any type (surgery, RadioTherapy, chemotherapy, targeted agents) of previous treatment and any line of treatment are eligible.
- Age ≥18 years.
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol; those conditions should be discussed with the patient before registration in the trial.
- Before patient registration, written informed consent must be given according to ICH/GCP (International Conference on Harmonisation/Good Clinical Practice), and national/local regulations.
Exclusion
Key Trial Info
Start Date :
September 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2022
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT01838577
Start Date
September 1 2013
End Date
March 1 2022
Last Update
March 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Marsden
Sutton, United Kingdom